vs

Side-by-side financial comparison of ESPEY MFG & ELECTRONICS CORP (ESP) and OCULAR THERAPEUTIX, INC (OCUL). Click either name above to swap in a different company.

OCULAR THERAPEUTIX, INC is the larger business by last-quarter revenue ($13.3M vs $12.1M, roughly 1.1× ESPEY MFG & ELECTRONICS CORP). ESPEY MFG & ELECTRONICS CORP runs the higher net margin — 23.1% vs -488.0%, a 511.1% gap on every dollar of revenue. On growth, ESPEY MFG & ELECTRONICS CORP posted the faster year-over-year revenue change (-10.8% vs -22.4%). ESPEY MFG & ELECTRONICS CORP produced more free cash flow last quarter ($-4.1M vs $-57.1M). Over the past eight quarters, ESPEY MFG & ELECTRONICS CORP's revenue compounded faster (21.3% CAGR vs -5.3%).

ESPEY MFG & ELECTRONICS CORP is a US-based manufacturer specializing in high-reliability power supplies, power conversion systems and specialized electronic components. It serves aerospace, defense, industrial and transportation sectors, delivering custom solutions for harsh environments to OEMs and government contractors across North America and select global markets.

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

ESP vs OCUL — Head-to-Head

Bigger by revenue
OCUL
OCUL
1.1× larger
OCUL
$13.3M
$12.1M
ESP
Growing faster (revenue YoY)
ESP
ESP
+11.6% gap
ESP
-10.8%
-22.4%
OCUL
Higher net margin
ESP
ESP
511.1% more per $
ESP
23.1%
-488.0%
OCUL
More free cash flow
ESP
ESP
$53.0M more FCF
ESP
$-4.1M
$-57.1M
OCUL
Faster 2-yr revenue CAGR
ESP
ESP
Annualised
ESP
21.3%
-5.3%
OCUL

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
ESP
ESP
OCUL
OCUL
Revenue
$12.1M
$13.3M
Net Profit
$2.8M
$-64.7M
Gross Margin
34.7%
88.0%
Operating Margin
25.3%
-526.5%
Net Margin
23.1%
-488.0%
Revenue YoY
-10.8%
-22.4%
Net Profit YoY
47.0%
-33.6%
EPS (diluted)
$0.99
$-0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESP
ESP
OCUL
OCUL
Q4 25
$12.1M
$13.3M
Q3 25
$9.1M
$14.5M
Q2 25
$9.6M
$13.5M
Q1 25
$10.3M
$10.7M
Q4 24
$13.6M
$17.1M
Q3 24
$10.4M
$15.4M
Q2 24
$11.6M
$16.4M
Q1 24
$8.3M
$14.8M
Net Profit
ESP
ESP
OCUL
OCUL
Q4 25
$2.8M
$-64.7M
Q3 25
$2.2M
$-69.4M
Q2 25
$2.9M
$-67.8M
Q1 25
$1.7M
$-64.1M
Q4 24
$1.9M
$-48.4M
Q3 24
$1.6M
$-36.5M
Q2 24
$1.9M
$-43.8M
Q1 24
$1.0M
$-64.8M
Gross Margin
ESP
ESP
OCUL
OCUL
Q4 25
34.7%
88.0%
Q3 25
35.4%
87.8%
Q2 25
39.3%
85.6%
Q1 25
28.6%
88.2%
Q4 24
23.2%
92.8%
Q3 24
26.8%
89.9%
Q2 24
27.6%
90.8%
Q1 24
25.0%
91.0%
Operating Margin
ESP
ESP
OCUL
OCUL
Q4 25
25.3%
-526.5%
Q3 25
22.7%
-472.3%
Q2 25
27.4%
-502.6%
Q1 25
17.0%
-597.5%
Q4 24
14.9%
-296.1%
Q3 24
16.5%
-298.2%
Q2 24
18.4%
-265.1%
Q1 24
13.2%
-214.0%
Net Margin
ESP
ESP
OCUL
OCUL
Q4 25
23.1%
-488.0%
Q3 25
23.9%
-477.3%
Q2 25
30.6%
-503.9%
Q1 25
16.5%
-598.7%
Q4 24
14.0%
-283.3%
Q3 24
15.3%
-236.6%
Q2 24
16.3%
-266.3%
Q1 24
12.5%
-438.9%
EPS (diluted)
ESP
ESP
OCUL
OCUL
Q4 25
$0.99
$-0.27
Q3 25
$0.76
$-0.38
Q2 25
$1.07
$-0.39
Q1 25
$0.63
$-0.38
Q4 24
$0.71
$-0.25
Q3 24
$0.61
$-0.22
Q2 24
$0.73
$-0.26
Q1 24
$0.40
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESP
ESP
OCUL
OCUL
Cash + ST InvestmentsLiquidity on hand
$17.8M
$737.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$53.2M
$654.3M
Total Assets
$85.2M
$808.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESP
ESP
OCUL
OCUL
Q4 25
$17.8M
$737.1M
Q3 25
$22.2M
$344.8M
Q2 25
$18.9M
$391.1M
Q1 25
$13.9M
$349.7M
Q4 24
$8.0M
$392.1M
Q3 24
$4.8M
$427.2M
Q2 24
$4.4M
$459.7M
Q1 24
$5.6M
$482.9M
Stockholders' Equity
ESP
ESP
OCUL
OCUL
Q4 25
$53.2M
$654.3M
Q3 25
$51.0M
$258.2M
Q2 25
$50.8M
$305.9M
Q1 25
$46.3M
$265.9M
Q4 24
$44.8M
$315.3M
Q3 24
$42.5M
$352.0M
Q2 24
$41.3M
$377.7M
Q1 24
$39.3M
$408.0M
Total Assets
ESP
ESP
OCUL
OCUL
Q4 25
$85.2M
$808.1M
Q3 25
$84.8M
$410.9M
Q2 25
$79.1M
$451.3M
Q1 25
$72.8M
$405.9M
Q4 24
$60.2M
$457.9M
Q3 24
$57.6M
$490.4M
Q2 24
$56.5M
$517.1M
Q1 24
$53.1M
$538.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESP
ESP
OCUL
OCUL
Operating Cash FlowLast quarter
$-2.8M
$-54.2M
Free Cash FlowOCF − Capex
$-4.1M
$-57.1M
FCF MarginFCF / Revenue
-34.1%
-430.9%
Capex IntensityCapex / Revenue
10.9%
21.4%
Cash ConversionOCF / Net Profit
-1.00×
TTM Free Cash FlowTrailing 4 quarters
$11.7M
$-216.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESP
ESP
OCUL
OCUL
Q4 25
$-2.8M
$-54.2M
Q3 25
$5.7M
$-50.7M
Q2 25
$2.8M
$-55.2M
Q1 25
$11.5M
$-44.7M
Q4 24
$5.4M
$-39.4M
Q3 24
$1.4M
$-36.6M
Q2 24
$3.2M
$-24.8M
Q1 24
$1.4M
$-33.9M
Free Cash Flow
ESP
ESP
OCUL
OCUL
Q4 25
$-4.1M
$-57.1M
Q3 25
$4.4M
$-56.7M
Q2 25
$915.3K
$-56.5M
Q1 25
$10.5M
$-46.6M
Q4 24
$4.5M
$-39.6M
Q3 24
$724.8K
$-36.6M
Q2 24
$2.6M
$-25.5M
Q1 24
$379.1K
$-34.1M
FCF Margin
ESP
ESP
OCUL
OCUL
Q4 25
-34.1%
-430.9%
Q3 25
48.7%
-390.0%
Q2 25
9.5%
-419.7%
Q1 25
101.8%
-435.6%
Q4 24
33.0%
-232.0%
Q3 24
6.9%
-237.6%
Q2 24
22.2%
-155.4%
Q1 24
4.6%
-231.1%
Capex Intensity
ESP
ESP
OCUL
OCUL
Q4 25
10.9%
21.4%
Q3 25
14.2%
41.2%
Q2 25
19.3%
9.3%
Q1 25
9.3%
18.1%
Q4 24
6.5%
1.2%
Q3 24
6.4%
0.6%
Q2 24
5.7%
4.5%
Q1 24
12.5%
1.7%
Cash Conversion
ESP
ESP
OCUL
OCUL
Q4 25
-1.00×
Q3 25
2.64×
Q2 25
0.95×
Q1 25
6.72×
Q4 24
2.82×
Q3 24
0.87×
Q2 24
1.71×
Q1 24
1.37×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESP
ESP

ASC606$11.3M93%
Other$855.0K7%

OCUL
OCUL

Segment breakdown not available.

Related Comparisons